Additionally, the randomized phase III MPACT trial compared gemcitabine plus albumin-bound paclitaxel versus gemcitabine alone in patients with metastatic pancreatic cancer and no prior chemotherapy and demonstrated improved response and survival in the gemcitabine plus albumin-bound paclitaxel group (14, 38). Here, ALB is linked to familial pancreatic carcinoma.